Clinical trial · Interventional
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma
NCT00025467CI-TRIAL-00009092completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Adenoacanthoma | Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation | ALIAS | 0.90 |
| Endometrial Adenocarcinoma | Endometrial Adenocarcinoma | CURATED_BROADER | 0.80 |
| Endometrial Adenosquamous Cell Carcinoma | — | UNRESOLVED | — |
| Endometrial Clear Cell Carcinoma | — | UNRESOLVED | — |
| Endometrial Papillary Serous Carcinoma | — | UNRESOLVED | — |
| Recurrent Endometrial Carcinoma | Endometrial Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| thalidomide | Drug | Thalidomide | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (thalidomide)
- description
- Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- interventionNames
- Drug: thalidomide
- Other: laboratory biomarker analysis
Primary outcomes (2)
- measure
- Proportion of patients alive and progression-free
- timeFrame
- 6 months
- measure
- Frequency of adverse events assessed by CTC
- timeFrame
- Up to 6 years
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed endometrial carcinoma * Recurrent or persistent (refractory to curative therapy or established treatment) * No sarcomas * At least 1 unidimensionally measurable lesion * At least 20 mm by conventional techniques, including palpation, plain x-ray, CT scan, or MRI * At least 10 mm by spiral CT scan * At least 1 target lesion outside the area of prior radiotherapy * Received 1 prior chemotherapy regimen for endometrial carcinoma * Initial treatment may include high-dose therapy, consolidation, or extended therapy * No more than 1 additional cytotoxic regimen for recurrent or persistent disease * No non-cytotoxic chemotherapy for recurrent or persistent disease * Ineligible for higher priority GOG protocols (any active GOG phase III protocol for the same patient population) * No documented brain metastases since diagnosis of cancer * Patients with stable CNS deficits allowed provided there are no brain metastases, as confirmed by CT scan or MRI * Performance status - GOG 0-2 if patient received 1 prior regimen * Performance status - GOG 0-1 if patient received 2 prior regimens * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * SGOT no greater than 2.5 times ULN * Alkaline phosphatase no greater than 2.5 times ULN * Creatinine no greater than 1.5 times ULN * Creatinine clearance greater than 60 mL/min * Not pregnant * Negative pregnancy test * Fertile patients must use 2 methods of effective contraception for 4 weeks before, during, and for 4 weeks after study participation * No active infection requiring antibiotics * No sensory or motor neuropathy greater than grade 1 * No other invasive malignancy within the past 5 years except non-melanoma skin cancer * No documented seizure disorders since diagnosis of cancer * Patients with a history of seizure disorders allowed provided that the seizures have been stable (i.e., no seizure within the past 12 months) while on an appropriately monitored treatment regimen * At least 3 weeks since prior biologic or immunologic agents directed at malignancy * No prior thalidomide * See Disease Characteristics * At least 3 weeks since prior chemotherapy directed at malignancy and recovered * At least 1 week since prior hormonal therapy directed at malignancy * Concurrent hormone replacement therapy allowed * See Disease Characteristics * At least 3 weeks since prior radiotherapy directed at malignancy and recovered * No prior radiotherapy to more than 25% of marrow-bearing areas * Recovered from prior surgery * At least 3 weeks since any other prior therapy directed at malignancy * No prior cancer therapy that would preclude study participation * No concurrent bisphosphonates (e.g., zoledronate)
References
Publications (0)
Data not yet available
No reference posted for this study.